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Background and Need 
 
 Substance use disorders (SUDs) are a rapidly evolving public health crisis. SUDs are 
associated with a myriad of adverse consequences including overdose, contraction of infectious 
diseases, and development of psychiatric comorbidities such as depression (World Drug Report, 
2020). While pharmacotherapies exist for certain SUDs, most current medications require daily 
adherence to self-administration, and long-term abstinence rate remain low (Mattick et al., 2001). 
Additionally, there are currently no FDA-approved medications to treat stimulant use disorders 
(such as cocaine, amphetamines), benzodiazepine use disorder and cannabis use disorder. 
Consequently, there is a clear need for novel, efficacious pharmacotherapies for treatment of SUDs. 
Multiple prior studies including both randomized controlled trials and naturalistic studies 
suggest that medications known as psychedelics have potential therapeutic benefit in the treatment 
of addictions and other psychiatric disorders. In a dose-dependent manner, this class of compounds 
is associated with novel psychoactive experiences characterized by dream-like states, altered 
sensory perceptions, and an increased sense of universal connectedness. Psychedelic compounds 
are associated with a high safety profile with extremely low levels of morbidity and mortality, and 
limited evidence of any physical dependence (Johnson et al., 2018; Nichols, 2016).  
Investigational study using these compounds for the treatment of mental health disorders 
has escalated in the past decade. Psilocybin and 3,4-Methylenedioxymethamphetamine (MDMA) 
have been particularly well studied, and in the past three years, the FDA granted “breakthrough 
therapy” designation to these medications for treatment resistant depression and post-traumatic 
stress disorder (PTSD), respectively. While these medications are considered somewhat 
controversial due to their unique psychoactive effects, a previous national level survey of the 
general population found that a majority of Americans supported research and potentially clinical 
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use of these medications for mental health disorders. Despite increasing evidence of efficacy in 
SUD treatment however, no prior study has investigated whether individuals with SUDs would be 
open to treatment with these new therapeutic agents. My hypothesis was that individuals with a 
SUD would demonstrate differential acceptance of these treatment modalities as a function of prior 
awareness of these medications.  
Problem Statement 
 Although psychedelic medications appear efficacious in SUD treatment, no prior study has 
investigated whether individuals with SUDs would be open to treatment with this class of 
medications. Further, while prior clinical trials have been conducted using various psychedelics to 
treat patients with a SUD, individuals already involved in psychedelic therapy research may not 
display the same attitudes and opinions with SUD individuals who have not received these 
therapies.  
Innovation 
Collectively, the analyses provide critical insights into patient-perspectives on the use of 
these novel psychotherapeutics for the treatment of SUDs. This study had the advantage of utilizing 
previously completed nationwide survey data in a large population (N=920). Furthermore, this 
study provides essential information that will direct future research recruitment efforts and clinical 
considerations using these treatments and will inform future studies for this urgent public health 
need. 
CHAPTER II 
REVIEW OF THE LITERATURE 
 
Substance use disorders (SUDs) are a rapidly evolving public health issue 
SUDs affect an estimated 35.6 million individuals worldwide (World Drug Report, 2020). 
SUDs can lead to many adverse clinical consequences including contraction of infectious diseases, 
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overdose, and the development of comorbid psychiatric disorders (World Drug Report, 2020). 
SUDs are classified on a range from mild to moderate to severe, with severity being dependent on 
how many criteria are met according to the Diagnostic and Statistical Manual of Mental Disorders 
(DSM).  Criteria include physiologic changes (i.e. craving, tolerance, and withdrawal symptoms), 
psychosocial problems (i.e. legal issues, occupational impairment, use in hazardous situations, 
decreased recreational enjoyment, family or social problems), and use despite harms to mental or 
physical well-being.  
Addiction is generally characterized as a recurring cycle of binging/intoxication, 
withdrawal/negative affect, and preoccupation/anticipation also known as “craving” (Koob et al., 
2016). This cycle worsens over time and involves changes in reward, stress, and executive function 
systems in the brain (Koob et al., 2016). Additionally, changes in brain activity associated with a 
mental illness, may increase an individual’s risk to abuse substances by enhancing the drug’s 
rewarding effects, reducing awareness of negative effects, and/or alleviating unpleasant symptoms 
of the mental disorder or the side effects of the medication used to treat it (NIDA, 2020).  
When a drug of abuse is taken, origins and terminal areas of the ascending 
mesocorticostriatal dopamine systems are activated, largely contributing to the rewarding 
properties of these substances (Koob et al., 2016). When drugs of abuse are taken at doses 
producing intoxication, there is a fast and profound release of dopamine into the ventral striatum 
which binds and activates dopamine D1 receptors, producing the rewarding effects and triggering 
conditioned responses to the stimulus (Koob et al., 2016). Understanding changes at the molecular, 
cellular, and neurocircuitry levels that allow for the transition from an occasional substance user to 
a chronic substance user who suffers from loss of control in their drug intake is critical for the 
treatment of SUDs (Koob et al., 2016). Knowledge of relevant brain circuits, neurotransmitters, 
and neuromodulators has evolved substantially over the years and now include y-aminobutyric acid 
(GABA), glutamate, serotonin, acetylcholine, and endocannabinoid systems (Koob et al., 2016). 
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Substances of abuse work via neurotransmitter-specific neuroplasticity circuits in order to 
rewire executive function circuits, motivational circuits, and stress circuits resulting in poor 
inhibitory control and decision making (Koob et al., 2016). It is this rewiring that can lead to a once 
neutral stimuli now being associated with positive reward commonly referred to as reinforcement 
(Koob et al., 2016). When reinforcement occurs, it strengthens the rewiring of these 
neurotransmitter-specific reward circuits, making it much harder to stop using the drug and the 
motivation to binge again even greater. Furthermore, this repeated cycle of binging to intoxication 
and subsequent strengthening of reward circuits leads to the development of tolerance for the drug 
at the current dose being taken.  
When tolerance occurs, a larger dose of the drug of abuse must be taken in order to achieve 
the same rewarding effects once felt previously, substantially increasing one’s risk of overdose. 
Prior brain imaging studies have shown amphetamine/methylphenidate-induced striatal dopamine 
responses are 50% lower in detoxified users compared to an 80% lower response in active abusers 
(Koob et al., 2016). While experiencing drug tolerance, if the individual does not take a larger dose 
of the drug of abuse, they will begin to experience the withdrawal stage of addiction.  
The withdrawal stage consists of several negative affects including increased stress, 
irritability, malaise, and even emotional pain (Koob et al., 2016). This is largely due to the 
recruitment of key brain stress systems such as corticotropin releasing factor (CRF), 
norepinephrine, and dynorphin to the amygdala (Koob et al., 2016). This decrease in reward and 
increase in stress function results in craving which drives the individual to compulsively seek out 
more of the drug, potentially engaging in risky activities to do so (Koob et al., 2016). These cravings 
are largely influenced by cues the individual has come to associate with the drug of abuse. Cues 
may vary widely from person to person, but can include a certain time of day, a particular room in 
the house, the sight of drug paraphernalia, etc. These cues that the individual has come to associate 
with the drug of abuse lead to a dopamine release in the striatum, amygdala, and prefrontal cortex 
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along with opioid peptide release in the anterior cingulate and frontal cortex (Koob et al., 2016), 
fueling the individual’s craving.   
Current therapies for SUDs are inadequate and novel treatments are needed 
There are currently several medications for SUDs on the market today which have been 
granted FDA approval. These include pharmacotherapies for tobacco use disorder, alcohol use 
disorder and opioid use disorder. While these SUDs can be treated with medications, many existing 
pharmacotherapies require daily adherence to medication self-administration, and long-term 
abstinence rates remain low (Mattick et al., 2001). Additionally, individuals with co-occurring 
mental health disorders and substance use disorders report lower rates of treatment success, higher 
rates of psychiatric hospitalizations, and a higher prevalence of suicide (World Drug Report, 2020). 
It has been shown that only 18 % of addiction treatment programs and 9 % of mental health 
programs were able to provide pertinent treatment to dual diagnosis individuals in the United States 
(McGovern et al., 2014).   
In the case of opioid use disorder, there are currently only 3 main FDA approved 
medications authorized for treatment, naltrexone, methadone, and buprenorphine - naloxone. 
Treatment with methadone may be used short-term in order to detoxify patients from opioids, 
however, it is also commonly used in long-term treatment provided the individual attends 
mandatory counseling due to the risks involved with methadone treatment (Butelman et al., 2017). 
Methadone can be fatal if taken in overdose and may also increase one’s risk of severe liver disease 
with paired use of other substances such as alcohol or psychotropic medications like 
benzodiazepines and barbiturates (Kreek, Oratz, & Rothschild, 1978).  
The opioid partial agonist medication, buprenorphine - naloxone, has a lower risk or 
overdose than methadone due to its ceiling effect on respiratory depression (Butelman et al., 2017). 
Drug counseling is highly recommended for treatment and patients must be seen at frequent 
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intervals until a stable dosage is achieved (Butelman et al., 2017). This can lead to a significant 
reduction in long term abstinence rates due to patient drop out. Additionally, current FDA approved 
medications to treat alcohol and tobacco use disorders require daily medication self-administration, 
sometimes multiple times a day, further contributing to low long-term abstinence rates for these 
SUDs. Moreover, there are currently no FDA-approved medications to treat stimulant use disorders 
(such as cocaine and amphetamines), benzodiazepine use disorder, or cannabis use disorder. 
Collectively, this demonstrates a substantial need for novel, efficacious pharmacotherapies for 
treatment of SUDs. 
Novel psychoactive medications may improve ability to maintain abstinence across a 
broad variety of SUDs 
A class of compounds with unique psychoactive effects called psychedelics, have shown 
early evidence of efficacy in the treatment of substance use disorders. In a dose dependent fashion, 
psychedelic compounds can temporarily produce dream-like states, altered sensory perceptions, 
and increased sense of universal connectedness.  Unlike most existing SUD pharmacotherapies, 
these medications appear to improve ability to maintain abstinence across a wide spectrum of SUDs 
and may improve ability to maintain abstinence with only one or a few medication administrations 
(Curran et al., 2018). Evidence demonstrates that psychedelics have a high safety profile with 
extremely low levels of morbidity and mortality, and studies show limited evidence of any physical 
dependence (Johnson et al., 2018; Nichols, 2016). Psilocybin and 3,4-
Methylenedioxymethamphetamine (MDMA) have been particularly well studied, and in the past 
three years, the FDA granted “breakthrough therapy” designation to these medications for treatment 
resistant depression and post-traumatic stress disorder (PTSD), respectively.  Breakthrough therapy 
is granted when preliminary clinical data indicates that a drug intended to treat a serious medical 
condition has demonstrated substantial improvement over the currently available therapies 
(Commissioner, O., 2018).  
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Psilocybin is a naturally occurring psychedelic produced in a variety of mushrooms. 
Psilocybin broken down to its pharmacologically activated form, psilocin, in the gastrointestinal 
tract and kidneys (Psilocybin, 2016). Once converted to psilocin, it acts as a high-affinity agonist 
at several serotonin 5-HT receptors (Psilocybin, 2016). The most common of these being 5-HT2A 
receptors which are especially prominent in the prefrontal cortex, resulting in increased cortical 
activity (Psilocybin, 2016). Due to dysfunction in the monoamine systems of serotonin (5-HT) seen 
in SUDs (Bas et al. 2017), psilocin’s action on the serotonergic pathway makes psilocybin a key 
drug of interest for the treatment of SUDs.  
Psilocybin has demonstrated efficacy in the treatment of tobacco use disorder with 80% of 
participants showing seven-day point prevalence abstinence at 6th month follow-up (Johnson et al., 
2014). A study on alcohol use disorder showed that participants reporting heavy drinking days 40% 
of the time at baseline were able to reduce heavy drinking days to <20% after just one or two 
treatment sessions (Bogenschutz et al., 2015). Furthermore, a study investigating treatment-
resistant depression found that one week after 2 sessions, 71% of participants had >50% reduction 
in depression severity and 58% were completely in remission (Davis et al., 2020).  
Ketamine is a racemic mixture of two enantiomers, esketamine (S-Ketamine) and 
arketamin (R-Ketamine) (Himmelseher et al. 2008). Ketamine first gained FDA approval in 1970 
for its human use as an anesthetic (Jansen, 2000). Much research has gone into Ketamine since and 
it has shown great promise in the treatment of SUDs. A previous study demonstrated that after 3 
treatments with ketamine combined with therapy, 50% of study participants were able to abstain 
from using heroin fully for over 1 year (Jones et al., 2018). In a related study with heavy alcohol 
users, it was discovered that nearly 2/3 of participants were able to maintain abstinence for over 
one year after a single session of ketamine in conjunction with psychotherapy (Jones et al., 2018). 
Furthermore, several other recent trials in cocaine users have shown that motivation to quit 
increases following a ketamine treatment. (Jones et al., 2018).  
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Additional studies have demonstrated an anti-depressant effect when participants were 
given sub-anesthetic doses of ketamine, leading to ultra-rapid remission of severe depression 
symptoms including thoughts of suicide (Jones et al., 2018). This anti-depressant effect is 
hypothesized to be mediated by ketamine’s action as an NMDA receptor (NMDAR) antagonist 
(Strasburger et al., 2017). Antagonism of the NMDAR by Ketamine was hypothesized to increase 
overall activity in the prefrontal cortex due to NMDAR inhibition expressed on GABAergic 
interneurons (Zanos et al., 2018). This increase in activity produces various synaptic improvements 
including structural increase of spine densities at synaptic proteins, ultimately hypothesized to 
improve one’s ability to learn new behaviors which may prove to be invaluable in the treatment of 
SUDs (Jones et al. 2018). 
3,4-Methylenedioxymethamphetamine (MDMA) acts as an indirect serotonin agonist, 
acting on the serotonin transporter where it is then transported to the nerve terminal (Baker et al. 
2004). Being inside the terminal affects the amount of serotonin which can be stored within vesicles 
and thus leads to a significant increase in serotonin release into the synapse (Baker et al. 2004). 
Additionally, MDMA increases release of dopamine and noradrenaline in what is believed to be a 
similar manner (Baker at al., 2004). In 2016, the FDA approved MDMA for phase 3 clinical trials 
as a treatment for post-traumatic stress disorder (PTSD), which is a condition that commonly occurs 
alongside addictions. A prior study from 2012 demonstrated that with 3 doses of MDMA 
administered under a psychiatrist's guidance, the patients reported a 56% decrease of severity of 
symptoms on average, and 66% no longer met the criteria for having PTSD by the end of the study 
with improvements lasting more than a year after therapy (Mithoefer et al., 2012). 
Target population support for psychedelic treatments is unknown 
Previous work has shown strong overall public support for research into this medication 
class (McCarriston, 2017). In a 2017 national survey of the general population, 53% of all 
respondents supported medical research into psychedelic drugs.  A majority (63%) also said they 
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would personally be open to medical treatment with psilocybin, ketamine, or MDMA if they had a 
medical condition for which it was proven effective and safe (McCarriston, 2017). However, it is 
unknown whether individuals with SUDs have similar levels of support. A majority of individuals 
with SUDs will have tried more than one addictive substance, which suggests that they may have 
previously tried psychedelic compounds (McCance-Katz, 2019).  However, SUDs are also 
characterized by avoidant thought processes however, and individuals often report using substances 
to cope with difficult feelings.  
Given that psychedelic compounds can be associated with challenging psychoactive 
experiences, it is thus unclear whether individuals with SUDs will endorse a similar level of support 
to the general population, or whether they will endorse particular concerns about these prospective 





A cross-sectional survey study was designed and administered in order to analyze patient-
perspectives on the use of these novel psychotherapeutics for the treatment of SUDs. Prior to 
completion of the main survey, potential participants were required to first complete a pre-screener 
questionnaire.  This questionnaire evaluated several criteria for SUDs in order to ensure that only 
those self-reporting criteria matching that of a SUD would be offered the opportunity to complete 
the full survey. IP constraints were set up to prevent participants from taking the survey more than 
once. 
Recruitment  
Recruitment was conducted primarily through advertisements placed on the internet (i.e. 
Craigslist).  Both pre-screening and the survey were conducted using the secure web database, 
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REDCap. REDCap is primed to support online and offline data capture for research studies and 
operations.  
Inclusion Criteria  
To have been considered for inclusion in the study, participants must have been (1) over 
the age of 18, of any gender, race or ethnicity, (2) able to comprehend English, (3) able to provide 
informed consent and function at an intellectual level sufficient to allow accurate completion of the 
assessment instruments, (4) self-reporting at least 2 criteria for SUD, and (5) have used a substance 
of abuse at least once in the past month.  
Exclusion Criteria  
Potential participants were excluded if they (1) did not self-reporting at least 2 criteria for 
a SUD, (2) did not report using a substance of abuse at least once per month, (3) denied ever 
wanting to cut back on or stop using a substance of abuse, or (4) did not give their informed consent 
to participate in the study. 
Screening and Informed Consent  
Initial screening eligibility using the inclusion and exclusion criteria was conducted using 
a pre-screener questionnaire hosted via REDCap. Participants were informed that participation in 
the study was voluntary, and they could discontinue at any time. Participants were provided with 
an overview of the study procedures in advance.  
Assessment Procedures  
Following completion of informed consent, and provided that all inclusion and exclusion 
criteria were satisfied, eligible participants proceeded to take the “Opinions on Psychedelic 
Therapy” main survey. The survey took approximately 20 minutes to complete. The survey was 
anonymous, but participants were asked basic questions about themselves such as their age, gender, 
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race, and use of alcohol and various substances. Participants went on to answer questions regarding 
(1) their level of support for the psychotherapeutics psilocybin, ketamine and MDMA being used 
in medical trials, (2) whether or not they believe these psychotherapeutics could be a beneficial 
treatment for people suffering with addictions, and (3) whether or not they themselves would be 
willing to participate in one of these trials. The psychotherapeutics psilocybin, ketamine, and 
MDMA were specifically chosen to asses individual level of support as there have been multiple 
prior studies conducted which demonstrate their efficacy in the treatment of addictions and other 
psychiatric disorders and thus they would be most likely to continue to be used in future medical 
trials. 
Participants were then asked to select from a list of 14 concerns regarding the use of 
psychedelics (psilocybin, ketamine, MDMA, or other psychedelic medications) to reduce or stop 
using alcohol or other drugs. The concerns listed were comprised of common fears that are 
associated with perceived possible consequences that might arise from taking a psychotherapeutic 
(fear of a bad trip, fear of losing one’s mind, fear of job loss, etc.). Participants could select any 
number of concerns from this list or a “N/A” option if they had no concerns.  
Participant Compensation  
Participants were eligible to be compensated for their time with a $15 Amazon gift card. 
This gift card would be sent to their email address. If the participant did not wish to provide their 
email address, they may still take the survey, but they would not be able to receive compensation. 
Data Analytic Procedure 
All data from this survey was collected and managed using the secure REDCap (Research 
Electronic Data Capture) database. Furthermore, all data was analyzed using the SPSS statistical 
software platform. Baseline demographic characteristics were collected from all participants and 
descriptive statistics for the sample population were analyzed.  
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Research Questions and Hypotheses  
AIM 1 
To determine acceptance rates of the use of psychedelics as a therapeutic modality among 
individuals self-reporting SUDs. Based on previous studies which suggest that higher levels of 
education are associated with increased levels of acceptance of these new treatments in the general 
population, I hypothesized that prior knowledge of these treatment modalities would have the 
greatest impact on the level of support for these treatments. To test this hypothesis, we quantified 
the level of support for the use of psilocybin, ketamine, and MDMA as a function of prior 
knowledge of these psychedelic medications. Taken together, these data detail the role of how 
public awareness of these novel treatments modulates the support for their use in research and 
clinical contexts.   
To test this hypothesis, the independent variable assessed was between prior psychedelic 
knowledge individuals and no prior psychedelic knowledge individuals. The dependent variable 
was characterized by the level of psychedelic support expressed between the two groups based on 
each individual’s ranked choices regarding the use of psychedelics in medical research. This was 
accomplished through use of Mann-Whitney U.  
AIM 2 
To characterize concerns about the therapeutic use of psychedelics among individuals self-
reporting SUDs. Given that these medications have unique psychoactive effects, I hypothesized 
that the number of concerns regarding the therapeutic use of psychedelics would be greatest in 
individuals who have never used psychedelics previously in contrast to those who had. We further 
explored whether prior use affects the type of concerns expressed. My prediction was that 
individuals not reporting prior use would be more likely to endorse concerns related to the 
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experience itself (i.e. fear of "going crazy") and that there would be no difference between groups 
on psychosocial concerns (i.e. fear of judgement from family).  
To test this hypothesis, the independent variable assessed was between prior psychedelic 
use individuals and no prior psychedelic use individuals. The dependent variable was characterized 
by number of psychedelic concerns expressed between the two groups and which groups 
demonstrated greater or fewer concerns. This was accomplished through use of Mann-Whitney U.   
Exploratory Hypothesis 
Acceptance rates for the use of psychotherapeutics will directly correlate with discrete 
concerns about the therapeutic use of these compounds. To test this hypothesis, the first 
independent variable assessed was between individuals who support medical trials with psilocybin, 
ketamine and MDMA and individuals who do not. An additional independent variable was 
characterized by whether individuals in each group had discrete concerns regarding psychedelic 
use. This was accomplished through use of a nominal regression. 
Bias, Problems and Alternative Strategies 
While the secondary analysis of existing data is widely accepted and well-validated for 
research purposes, its use of previously collected data is subject to bias and confounding as 
researchers must decide what variables to use when the outcomes are known (Penson, 2006). 
Confounding occurs when a differential distribution of unmeasured variables exists among the 
samples used to create a secondary dataset and can cause associations to exist when there are none 
(Penson, 2006). Design variables used in the study were applied in the analysis in order to remove 








 Substance use disorders (SUDs) present a rapidly evolving public health crisis and many 
individuals with SUDs fail to maintain abstinence despite adherence to current standard of care 
treatment options. Prior research has demonstrated compounds with unique psychoactive properties 
may improve ability to maintain abstinence across a variety of SUDs; examples of such compounds 
include psilocybin, ketamine, and 3,4-Methylenedioxymethamphetamine (MDMA). However, 
target population support for mental health treatment using these medications is unknown. In this 
study, a cross-sectional survey (n=919) was administered to analyze patient-level perspectives on 
the use of these novel psychotherapeutics for the treatment of SUDs. We hypothesized that 
individuals with SUDs would demonstrate differential acceptance of these treatment modalities as 
a function of prior awareness of these medications. The results showed that the majority of survey 
participants supported medical trials being conducted with psilocybin (72.1%), ketamine (71.6%), 
and MDMA (68.1%) in the future. Furthermore, survey respondents with prior knowledge of 
ketamine as a potential treatment option were significantly more in support of clinical trial research 
with ketamine compared to individuals without such prior awareness (3.96 vs 3.79; p= .005). 
However, there was no statistically significant difference in support for future research into 
psilocybin or MDMA based on prior knowledge of these potential treatment modalities. These 
results can be used to direct future research recruitment efforts and provide insight into clinical 
considerations that should be made when using these treatments. 
Introduction 
Substance use disorders (SUDs) are a rapidly evolving public health crisis. SUDs can lead 
to many adverse clinical consequences including contraction of infectious diseases, overdose, and 
the development of comorbid psychiatric disorders (World Drug Report, 2020). SUDs are classified 
on a range from mild to moderate to severe, with severity being dependent on how many criteria 
are met according to the Diagnostic and Statistical Manual of Mental Disorders (DSM).  Criteria 
include physiologic changes (i.e. craving, tolerance, and withdrawal symptoms), psychosocial 
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problems (i.e. legal issues, occupational impairment, use in hazardous situations, decreased 
recreational enjoyment, family or social problems), and use despite harms to mental or physical 
well-being. 
There are currently several medications for SUDs on the market today which have been 
granted FDA approval. These include pharmacotherapies for tobacco use disorder (TUD), alcohol 
use disorder (AUD) and opioid use disorder (OUD). While these SUDs can be treated with 
medications, many existing pharmacotherapies require daily adherence to medication self-
administration, and long-term abstinence rates remain low (Mattick et al., 2001). In the case of 
OUD, there are currently only 2 main FDA approved medications authorized for treatment, 
methadone, or buprenorphine/naloxone (Subutex) (Butelman et al., 2017). Treatment with 
methadone may be used short-term in order to detoxify patients from opioids, however, it is also 
commonly used in long-term treatment provided the individual attends mandatory counseling due 
to the risks involved with methadone treatment (Butelman et al., 2017). Methadone can be fatal if 
taken in overdose and may also increase one’s risk of severe liver disease with paired use of other 
substances such as alcohol or psychotropic medications like benzodiazepines and barbiturates 
(Kreek, Oratz, & Rothschild, 1978).  
The opioid partial agonist medication, buprenorphine/naloxone (Subutex), has a lower risk 
or overdose than methadone due to its ceiling effect on respiratory depression (Butelman et al., 
2017). Drug counseling is mandatory for treatment and patients must be seen at frequent intervals 
until a stable dosage is achieved (Butelman et al., 2017). This can lead to a significant reduction in 
long term abstinence rates due to patient drop out. Furthermore, individuals with co-occurring 
mental health disorders and substance use disorders report lower rates of treatment success, higher 
rates of psychiatric hospitalizations, and a higher prevalence of suicide (World Drug Report, 2020). 
It has been shown that only 18 % of addiction treatment programs and 9 % of mental health 
programs were able to provide pertinent treatment to dual diagnosis individuals in the United States 
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(McGovern et al., 2014). Additionally, there are currently no FDA-approved medications to treat 
stimulant use disorders (such as cocaine and amphetamines), benzodiazepine use disorder, or 
cannabis use disorder.  
Novel psychoactive medications may improve ability to maintain abstinence across a broad 
variety of SUDs. A class of compounds with unique psychoactive effects called psychedelics, have 
shown early evidence of efficacy in the treatment of substance use disorders. In a dose dependent 
fashion, psychedelic compounds can temporarily produce dream-like states, altered sensory 
perceptions, and increased sense of universal connectedness.  Unlike most existing SUD 
pharmacotherapies, these medications appear to improve ability to maintain abstinence across a 
wide spectrum of SUDs and may improve ability to maintain abstinence with only one or a few 
medication administrations (Curran et al., 2018). Evidence demonstrates that psychedelics have a 
high safety profile with extremely low levels of morbidity and mortality, and studies show limited 
evidence of any physical dependence (Johnson et al., 2018; Nichols, 2016). Psilocybin and 3,4-
Methylenedioxymethamphetamine (MDMA) have been particularly well studied, and in the past 
three years, the FDA granted “breakthrough therapy” designation to these medications for treatment 
resistant depression and post-traumatic stress disorder (PTSD), respectively.  Breakthrough therapy 
is granted when preliminary clinical data indicates that a drug intended to treat a serious medical 
condition has demonstrated substantial improvement over the currently available therapies 
(Commissioner, O., 2018).   
Previous work has shown strong overall public support for research into this medication 
class (McCarriston, 2017). In a 2017 national survey of the general population, 53% of all 
respondents supported medical research into psychedelic drugs.  A majority (63%) also said they 
would personally be open to medical treatment with psilocybin, ketamine, or MDMA if they had a 
medical condition for which it was proven effective and safe (McCarriston, 2017). However, it is 
unknown whether individuals with SUDs have similar levels of support. A majority of individuals 
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with SUDs will have tried more than one addictive substance, which suggests that they may have 
previously tried psychedelic compounds (McCance-Katz, 2019).  However, SUDs are also 
characterized by avoidant thought processes however, and individuals often report using substances 
to cope with difficult feelings.  
Given that psychedelic compounds can be associated with challenging psychoactive 
experiences, it is thus unclear whether individuals with SUDs will endorse a similar level of support 
to the general population, or whether they will endorse particular concerns about these prospective 
new treatment modalities. 
Methods 
Study Design and Recruitment   
 A cross-sectional survey study was designed and administered to 932 participants in order 
to analyze patient-level perspectives on the use of these novel psychotherapeutics for the treatment 
of SUDs. 12 participants did not complete the survey. Prior to completion of the main survey, 
potential participants were required to first complete a pre-screener questionnaire.  This 
questionnaire evaluated several criteria for SUDs in order to ensure that only those self-reporting 
criteria matching that of a SUD would be offered the opportunity to complete the full survey. IP 
constraints were set up to prevent participants from taking the survey more than once. 
Recruitment was conducted primarily through advertisements placed on the internet (i.e. 
Craigslist).  Both pre-screening and the survey were conducted using the secure web database, 
REDCap. REDCap is primed to support online and offline data capture for research studies and 
operations. To have been considered for inclusion in the study, participants must have been (1) over 
the age of 18, of any gender, race or ethnicity, (2) able to comprehend English, (3) able to provide 
informed consent and function at an intellectual level sufficient to allow accurate completion of the 
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assessment instruments, (4) self-reporting at least 2 criteria for SUD, and (5) have used a substance 
of abuse at least once in the past month.  
Screening and Informed Consent  
Initial screening eligibility using the inclusion and exclusion criteria was conducted using 
a pre-screener questionnaire hosted via REDCap. Participants were informed that participation in 
the study was voluntary, and they could discontinue at any time. Participants were provided with 
an overview of the study procedures in advance.  
Assessment Procedures  
Following completion of informed consent, and provided that all inclusion and exclusion 
criteria were satisfied, eligible participants proceeded to take the “Opinions on Psychedelic 
Therapy” main survey. The survey took approximately 20 minutes to complete. The survey was 
anonymous, but participants were asked basic questions about themselves such as their age, gender, 
race, and use of alcohol and various substances. Participants went on to answer questions regarding 
(1) their level of support for the psychotherapeutics psilocybin, ketamine and MDMA being used 
in medical trials, (2) whether or not they believe these psychotherapeutics could be a beneficial 
treatment for people suffering with addictions, and (3) whether or not they themselves would be 
willing to participate in one of these trials. The psychotherapeutics psilocybin, ketamine, and 
MDMA were specifically chosen to asses individual level of support as there have been multiple 
prior studies conducted which demonstrate their efficacy in the treatment of addictions and other 
psychiatric disorders and thus they would be most likely to continue to be used in future medical 
trials. 
Participants were then asked to select from a list of 14 concerns regarding the use of 
psychedelics (psilocybin, ketamine, MDMA, or other psychedelic medications) to reduce or stop 
using alcohol or other drugs. The concerns listed were comprised of common fears that are 
19 
 
associated with perceived possible consequences that might arise from taking a psychotherapeutic 
(fear of a bad trip, fear of losing one’s mind, fear of job loss, etc.). Participants could select any 
number of concerns from this list or a “N/A” option if they had no concerns.  
Participant Compensation  
Participants were eligible to be compensated for their time with a $15 Amazon gift card. 
This gift card would be sent to their email address. If the participant did not wish to provide their 
email address, they may still take the survey, but they would not be able to receive compensation. 
Data Analytic Procedure 
All data from this survey was collected and managed using the secure REDCap (Research 
Electronic Data Capture) database. Furthermore, all data was analyzed using the SPSS statistical 
software platform. This study had the advantage of utilizing previously completed nationwide 
survey data in a large population (N=920). Baseline demographic characteristics were collected 
from all participants and descriptive statistics for the sample population were analyzed (Table 1). 
While the secondary analysis of existing data is widely accepted and well-validated for 
research purposes, its use of previously collected data is subject to bias and confounding as 
researchers must decide what variables to use when the outcomes are known (Penson, 2006). 
Confounding occurs when a differential distribution of unmeasured variables exists among the 
samples used to create a secondary dataset and can cause associations to exist when there are none 
(Penson, 2006). Design variables used in the study were applied in the analysis in order to remove 
bias. Confounding was controlled through the utilization of random samples. 
Results 
Of the 920 individuals who completed the survey, 919 questionnaires were included in the 
study as one participant did not complete questions regarding their prior use of psychedelics. Our 
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research found the overall majority of survey participants supported medical trials being conducted 
with psilocybin (72.1%), ketamine (71.6%), and MDMA (68.1%) in the future (Table 2a-c; Figure 
1a-c). To further determine acceptance rates of the use of psychedelics as a therapeutic modality 
among individuals self-reporting SUDs, we quantified the level of support for the use of psilocybin, 
ketamine and MDMA as a function of prior knowledge of these psychedelic medications. It was 
hypothesized that prior knowledge of these treatment modalities would have the greatest impact on 
the level of support for these treatments. 
To test this hypothesis, the independent variable assessed was between prior psychedelic 
knowledge individuals and no prior psychedelic knowledge individuals. The dependent variable 
was characterized by the level of psychedelic support expressed between the two groups based on 
each individual’s ranked choices regarding the use of psychedelics in medical research. This was 
accomplished through use of Mann-Whitney U due to a non-normal data distribution. Ketamine 
support scores were significant between participants with versus participants without prior 
awareness (3.96 vs 3.79; p=.005) (Table 3; Figure 2c-d), but there was no statistically significant 
difference regarding psilocybin or MDMA.  
In addition, we were interested to characterize concerns about the therapeutic use of 
psychedelics among individuals self-reporting SUDs. Given that these medications have unique 
psychoactive effects, it was hypothesized that the number of concerns regarding the therapeutic use 
of psychedelics would be greatest in individuals who have never used psychedelics previously in 
contrast to those who had. It was further explored whether prior use affects the type of concerns 
expressed. The prediction was that individuals not reporting prior use would be more likely to 
endorse concerns related to the experience itself (i.e. fear of "going crazy") and that there would be 
no difference between groups on psychosocial concerns (i.e. fear of judgement from family).  
To test this hypothesis, the independent variable assessed was between prior psychedelic 
use individuals and no prior psychedelic use individuals. The dependent variable was characterized 
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by total number of psychedelic concerns expressed between the two groups and which groups 
demonstrated greater or fewer concerns. This was accomplished through use of Mann-Whitney U 
due to a non-normal data distribution. There was no statistically significant difference found 
between an individual’s prior psychedelics use and overall concerns, having concerns related to the 
experience itself, nor a difference between groups regarding psychosocial concerns (Figure 3a-c).  
Additionally, our group went on to explore whether acceptance rates for the use of 
psychotherapeutics would directly associate with discrete concerns about the therapeutic use of 
these compounds. To test this, the first independent variable assessed was between individuals who 
support medical trials with psilocybin, ketamine and MDMA and individuals who do not. An 
additional independent variable was characterized by whether individuals in each group had 
discrete concerns regarding psychedelic use. This was accomplished using nominal regression.  
For psilocybin, one concern was identified to be significantly correlated with an 
individual’s level of support for medical trials being conducted with psilocybin in the future. For 
each unit of support increased, the odds of not selecting the concern “Fear that you would lose your 
sense of self” increased by 1.299 (95% CI, 1.063 to 1.588) times, a statistically significant effect, 
p = .011 (Table 5a). For Ketamine, two concerns were identified to be significantly correlated with 
an individual’s level of support for trying ketamine treatment themselves. For each unit of support 
increased, the odds of not selecting the concern “Fear that it would change you” increased by 1.207 
(95% CI, 1.009 to 1.444) times, a statistically significant effect, p = .039 (Table 5b). For each unit 
of support increased, the odds of not selecting the concern “Fear that you would harm yourself or 
others while on a bad trip” increased by 1.211 (95% CI, 1.009 to 1.453) times, a statistically 
significant effect, p = .040 (Table 5b). Additionally, one concern was significantly correlated with 
an individual’s level of support for ketamine treatment being beneficial for people with SUDs. For 
each unit of support increased, the odds of not selecting the concern “Fear that you would feel guilt 
22 
 
during your trip” increased by 1.233 (95% CI, 1.014 to 1.500) times, a statistically significant 
effect, p = .035 (Table 5b).  
For MDMA, two concerns were identified to be significantly correlated with an 
individual’s level of support for medical trials with MDMA being conducted in the future. For each 
unit of support reduction, the odds of not selecting the concern “Fear that it would cause you to "go 
crazy" or "lose your mind”” increased by 0.774 (95% CI, 0.648 to 0.925) times, a statistically 
significant effect, p = .005 (Table 5c). For each unit of support reduction, the odds of not selecting 
the concern “Fear that you would harm yourself or others while on a bad trip” increased by 0.791 
(95% CI, 0.658 to 0.951) times, a statistically significant effect, p = .013 (Table 5c). Two additional 
concerns were identified to be significantly correlated with an individual’s level of support for 
MDMA being beneficial for people with a SUD. For each unit of support reduction, the odds of not 
selecting the concern “Fear that you would lose your sense of self” increased by 0.749 (95% CI, 
0.618 to 0.908) times, a statistically significant effect, p = .003 (Table 5c). For each unit of support 
reduction, the odds of not selecting the concern “Fear that it would affect your employment” 
increased by 0.770 (95% CI, 0.630 to 0.941) times, a statistically significant effect, p = .011 (Table 
5c). Finally, two concerns were identified to be significantly correlated with an individual’s level 
of support for trying MDMA themselves if treatment was appropriate. For each unit of support 
reduction, the odds of not selecting the concern “Fear that you would feel guilt during your trip” 
increased by 0.843 (95% CI, 0.740 to 0.960) times, a statistically significant effect, p = .010 (Table 
5c). For each unit of support reduction, the odds of not selecting the concern “Fear that it would 
affect your employment” increased by 0.862 (95% CI, 0.751 to 0.990) times, a statistically 
significant effect, p = .036 (Table 5c). 
Discussion 
There is a clear need for novel, efficacious pharmacotherapies for treatment of SUDs. 
While pharmacotherapies exist for certain SUDs, most current medications require daily adherence 
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to self-administration, and long-term abstinence rate remain low. Additionally, there are currently 
no FDA-approved medications to treat stimulant use disorders (such as cocaine, amphetamines), 
benzodiazepine use disorder and cannabis use disorder. Multiple prior studies including both 
randomized controlled trials and naturalistic studies suggest that these psychotherapeutic 
medications have potential therapeutic benefit in the treatment of addictions and other psychiatric 
disorders. These compounds are associated with a high safety profile with extremely low levels of 
morbidity and mortality, and limited evidence of any physical dependence.  
A 2017 national survey of the general population by the data analytic group, YouGov, 
found that the majority of respondents supported future medical research into psilocybin (63%), 
ketamine (61%), and MDMA (61%) (McCarriston, 2017).  A majority (63%) also said they would 
personally be open to medical treatment with psilocybin, ketamine, or MDMA if they had a medical 
condition for which it was proven effective and safe (McCarriston, 2017).  
Until now it had been unknown whether individuals with SUDs would demonstrate similar 
levels of support. While multiple previous clinical trials have been conducted using psychedelics 
in an attempt to treat patients with a SUD, individuals already involved in psychedelic therapy 
research may not display the same attitudes and opinions with SUD individuals who have not 
received these therapies. This study found that the overall majority of survey participants with a 
SUD demonstrated a greater support for medical trials being conducted with psilocybin (72.1%), 
ketamine (71.6%), and MDMA (68.1%) in the future as compared to the general population (Table 
2a-c; Figure 1a-c). Additionally, it was discovered that the overall majority of survey participants 
with a SUD demonstrated a greater support for personally being open to medical treatment with 
psilocybin (75.6%), ketamine (74.3%), or MDMA (58.9%) if they had a medical condition for 
which it was proven effective and safe as compared to the general population (Table 4a-c; Figure 
4a-c).  It is important to note that most respondents (87%) in this study reported personal prior use 
of psychedelics in the past and more work needs to be done to determine whether this plays a role 
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in an individual’s acceptance. Moreover, this study did not investigate whether participants who 
had previously tried psychedelics had ever done so in an attempt to self-medicate. Multiple prior 
studies have shown that individuals who have used psychedelics to self-medicate for a variety of 
mental health disorders in the past, report psychedelics to be more efficacious at treating their 
symptoms compared to conventional treatments offered by medical professionals (Mason, N. L., 
& Kuypers, K. P. C. (2018), Hutten NR et al. (2019), Lea, T. et al. (2020)). It would be beneficial 
for future research to assess whether support differs with individuals who utilized psychedelics to 
self-medicate in the past.  
When investigating the impact prior awareness of psychedelic research had on support 
levels, it was found that ketamine support scores were significantly different between participants 
with versus participants without prior awareness (3.96 vs 3.79; p= .005) (Table 3; Figure 2c-d), but 
there was no statistically significant difference regarding psilocybin or MDMA. This difference in 
ketamine support scores could be explained by the fact that ketamine does not fall into the category 
of classic psychedelic and is more well-known for its dissociative properties. While statistical 
significance regarding ketamine support was reached, it is argued that a difference in support score 
of 3.96 vs 3.79 still demonstrates an overall acceptance of future research with or without prior 
awareness.  
It was further investigated whether individuals who had indicated prior use of psychedelics 
would differ in the number and types of concerns expressed regarding psychedelic therapies from 
individuals who had indicated no prior use of psychedelics. The data show there were no significant 
differences between prior use vs no prior use groups regarding the number and types of concerns 
expressed. While there was no significance reached, this is still beneficial information that can help 
direct future research recruitment efforts and clinical considerations using these treatments. Finally, 
in an effort to explore whether acceptance rates would directly correlate with discrete concerns 
regarding the therapeutic use of psychedelics, it was discovered that there were a handful of 
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concerns which significantly affected an individual’s level of support. It is beneficial for future 
studies to be aware of how these concerns correlate with individual’s acceptance rates so that an 
effort can be made to properly address them and adequately inform the public.   
This study provides essential information that will direct future research recruitment efforts 
and clinical considerations using these treatments and will inform future studies for this urgent 
public health need. There are numerous potential directions that can and should be investigated by 
future studies. Investigating how additional key demographics such as age, gender, race, education, 
etc. vary with individual levels of support would be an excellent starting point. Additionally, the 
majority of participants in this study were poly substance users, meaning they potentially suffered 
from multiple SUDs which may have had an impact on acceptance rates. One of the biggest 
challenge’s psychedelic research faces today is reversing the stigma that has been placed on these 
substances for decades. Future research should be prepared to investigate how political affiliation 
affects an individual’s level of support as that information will prove to be extremely vital in 




Table 1. Participant Demographics                                                                                                      
Age n (%) 
18 to 24 80 (8.7)  
25 to 34 447 (48.6) 
35 to 44 357 (38.8) 
45 to 54 29 (3.2) 
55+ 6 (0.7) 
Gender   
Male 651 (70.9) 




Other or prefer not 
to answer 
4 (0.4) 
Region   
Northeast 205 (22.3) 
Midwest 210 (22.9) 
South 231 (25.1) 
West 273 (29.7) 
Community   
Large city 406 (44.2) 
Midsized city 293 (31.9) 
Small city 180 (19.6) 
Suburban 35 (3.8) 
Rural 5 (0.5) 
Education   
No high school 5 (0.5) 
Some high school 12 (1.3) 
High school 
graduate or have 
GED 
84 (9.1) 
















86 (9.4)  
vi 
 
Relationship   
Married 619 (67.4) 
Never married 147 (16.0) 
Separated 59 (6.4) 




Widowed 12 (1.3) 
Children   
Yes 646 (70.3) 
No 273 (29.7) 
Race   
White 528 (57.5) 
Black or African 
American 
191 (20.8) 
Hispanic or Latino 137 (14.9) 
American Indian 
or Alaskan Native 
47 (5.1) 
Asian 26 (2.8) 
Native Hawaiian 
or Pacific Islander 
7 (0.8) 




abuse   
Alcohol 569 (61.9) 
Marijuana 566 (61.6) 
Tobacco 544 (59.2) 
Cocaine 234 (25.5) 
Opiates 143 (15.6) 
Amphetamines 133 (14.5) 
Benzodiazepines 112 (12.2) 
Other 6 (0.7) 
Number of substances used per month 
1 396 (0.43) 
2 126 (0.14) 
3 187 (0.20) 
4 90 (0.10) 









Table 2a. Overall Psilocybin Research Level of Support                                                                    
Based on these preliminary findings, and 
anything else you may know:  Do you 
support or oppose similar medical trials with 
psilocybin being conducted in the future? 




oppose 5 0.5 0.5 0.5 




228 24.8 24.8 27.9 
Support 432 47.0 47.0 74.9 
Strongly 
support 231 25.1 25.1 100.0 
Total 919 100.0 100.0  
 
Table 2b. Overall Ketamine Research Level of Support                                                                     
Based on these preliminary findings, and 
anything else you may know:  Do you 
support or oppose similar medical trials with 
ketamine being conducted in the future? 




oppose 5 0.5 0.5 0.5 




212 23.1 23.1 28.4 
Support 432 47.0 47.0 75.4 
Strongly 
support 226 24.6 24.6 100.0 







Table 2c. Overall MDMA Research Level of Support                                                                        
Based on these findings and what you may 
have known previously, do you support or 
oppose similar medical trials with MDMA 
being conducted in the future? 




oppose 9 1.0 1.0 1.0 




243 26.4 26.4 31.9 
Support 387 42.1 42.1 74.0 
Strongly 
support 239 26.0 26.0 100.0 
Total 919 100.0 100.0   
 
Table 3. Prior Awareness vs Research Level of Support                                                                     
  
Based on these preliminary 
findings, and anything else 
you may know:  Do you 
support or oppose similar 
medical trials with psilocybin 
being conducted in the 
future? 
Based on these preliminary 
findings, and anything else 
you may know:  Do you 
support or oppose similar 
medical trials with ketamine 
being conducted in the 
future? 
Based on these findings 
and what you may have 
known previously, do you 
support or oppose similar 
medical trials with MDMA 





94893.000 85426.000 91297.000 
Wilcoxon 
W 
145296.000 135829.000 141700.000 




0.883 0.005 0.253 
a. Grouping Variable: Have you ever previously heard about the use of psychedelic-type substances 










Table 4a. Overall Psilocybin “Would Try” Level of Support                                                              
If psilocybin is proven to be safe and effective 
for the treatment of addictions, would you or 
would you not try this treatment if it was 
appropriate for you? 




not 8 0.9 0.9 0.9 
Probably 




197 21.4 21.4 24.5 
Probably 
would 404 44.0 44.0 68.4 
Definitely 
would 290 31.6 31.6 100.0 
Total 919 100.0 100.0   
 
 
Table 4b. Overall Ketamine “Would Try” Level of Support                                                               
 
If ketamine is proven to be safe and effective 
for treatment after further trials, would you or 
would you not try this treatment if it was 
appropriate for you? 




not 9 1.0 1.0 1.0 
Probably 






192 20.9 20.9 25.8 
Probably 
would 403 43.9 43.9 69.6 
Definitely 
would 279 30.4 30.4 100.0 
Total 919 100.0 100.0   
 
Table 4c. Overall MDMA “Would Try” Level of Support                                                                  
If MDMA is proven to be safe and effective for 
treatment after further trials, would you or 
would you not try this treatment if it was 
appropriate for you? 




would 226 24.6 24.6 24.6 
Probably 












66 7.2 7.2 100.0 











Table 5a. Psilocybin Concerns vs Support                                                                                          
Question: 
Based on these preliminary findings, 
and anything else you may know:  Do 
you support or oppose similar medical 
trials with psilocybin being conducted in 
the future? B Std. Error Wald df Sig. Exp(B) 
95% Confidence 
Interval for Exp(B) 
Lower 
 Bound Upper Bound 
Concern: Fear that you would lose your sense of self  
0.261 0.102 6.519 1 0.011 1.299 1.063 1.588 
 
 
Table 5b. Ketamine Concerns vs Support                                                                                            
Question: 
If ketamine is proven to be 
safe and effective for 
treatment after further 
trials, would you or would 
you not try this treatment if 
it was appropriate for 
you? 










Fear that it would "change 
you" 0.188 0.091 4.258 1 0.039 1.207 1.009 1.444 
Fear that you would harm 
yourself or others while on 
a bad trip 
0.191 0.093 4.228 1 0.040 1.211 1.009 1.453 
          
Question: 
Do you think ketamine 
could be a beneficial 
treatment for people 
suffering with addictions? 

















Table 5c. MDMA Concerns vs Support                                                                                              
Based on these findings and what you may 
have known previously, do you support or 
oppose similar medical trials with MDMA 
being conducted in the future? 
B Std. Error Wald df Sig. Exp(B) 
95% Confidence 





Fear that it would cause you to "go crazy" or 
"lose your mind" -0.256 0.091 7.934 1 0.005 0.774 0.648 0.925 
Fear that you would harm yourself or others 
while on a bad tripa -0.235 0.094 6.214 1 0.013 0.791 0.658 0.951          
Do you think MDMA could or could not be a 
beneficial treatment for people suffering 
with PTSD? 
B Std. Error Wald df Sig. Exp(B) 
95% Confidence 





Fear that you would lose your sense of self  -0.289 0.098 8.697 1 0.003 0.749 0.618 0.908 
Fear that it would affect your employment -0.261 0.102 6.514 1 0.011 0.770 0.630 0.941 
         
If MDMA is proven to be safe and effective 
for treatment after further trials, would you 
or would you not try this treatment if it was 
appropriate for you? 
B Std. Error Wald df Sig. Exp(B) 
95% Confidence 





Fear that you would feel guilt during your 
trip -0.171 0.066 6.626 1 0.010 0.843 0.740 0.960 










Figure 1a. Overall Psilocybin Research Level of Support                                                                   
 
 




Figure 1c. Overall MDMA Research Level of Support                                                                   
 




Figure 2b. Psilocybin Research Support vs No Prior Awareness                                                        
 





Figure 2d. Ketamine Research Support vs No Prior Awareness                                                                                                                
 


















































Figure 4a. Overall Psilocybin “Would Try” Level of Support                                                                                                                         
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